Trials / Completed
CompletedNCT00828932
Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment
An Open Label, Single Dose Study of the Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate and establish whether lorcaserin dose adjustment is required in patients with mild or moderate hepatic impairment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lorcaserin |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2009-01-26
- Last updated
- 2019-09-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00828932. Inclusion in this directory is not an endorsement.